Abstract��
OBJECTIVE To study pharmacoeconomics using decision analysis. METHODS The data of 94 neonatal septicemia patients (37 cefuroxime recipients,34 cefotaxime recipients and 23 ceftazidime recipients) were evaluated. Decision analysis was used to evaluate the cost-effectiveness, and multiattribute utility theory(MAUT) was used to incorporate a humanistic evaluation of effectiveness, safety, cost and hospital stay. RESULTS The decision tree analysis revealed that the predicted costs of 3 cephalosporinses on the treatment of neonatal septicemia were RMB 3 990,4 074 and 3 770 yuans, respectively.The MAUT analysis showed that ceftazidime was the optimum medicine among the 3 cephalosporinses. CONCLUSION Decision analysis provides a standardized and flexible method for studying pharmacoeconomics.
2004, Vol. 40 